RESUMEN
We have previously hypothesized that the pro-inflammatory cytokine TNF alpha has a pivotal role in the pathogenesis of rheumatoid arthritis (RA). It mediates its effects by cross-linking surface p55 TNF receptors (TNF-R), which can be proteolytically cleaved to yield soluble fragments. Upon binding TNF alpha soluble TNF-R (sTNF-R) can inhibit its function. We investigated the enzymatic nature of the proteases involved in TNF-R cleavage, and found that this process is blocked by a synthetic inhibitor of matrix metallo-proteinase activity (MMP), BB-2275. Inhibition of TNF-R cleavage was observed in a number of different cell types, as detected by retention of surface bound TNF receptor and by less sTNF-R released into the cell supernatant. The augmentation of surface TNF-R expression was of biological relevance as TNF alpha-mediated necrosis of human KYM.1D4 rhabdosarcoma cells was enhanced approximately 15-fold in the presence of BB-2275. The addition of BB-2275 to rheumatoid synovial membrane cell cultures totally inhibited MMP activity and also significantly reduced the levels of soluble TNF alpha (P < 0.006), p55 sTNF-R (P < 0.006), and p75 sTNF-R (P < 0.004). Paradoxically, despite the reduction in soluble TNF alpha levels, the production of IL-1 beta, IL-6, and IL-8, cytokines whose production was previously demonstrated to be inhibited by the addition of neutralizing anti-TNF alpha antibody were not down-regulated by BB-2275. These results raise the interesting possibility that a close relationship exits between the enzyme(s) which process membrane-bound TNF alpha, and those involved in surface TNF-R cleavage. Furthermore our observations suggest that hydroxamate inhibitors of MMP activity which block TNF alpha secretion and TNF-R cleavage may not modulate down-stream effects of TNA alpha, and as such suggest that the precise specificity of these compounds will be highly relevant to their clinical efficacy in inflammatory diseases.
Asunto(s)
Artritis Reumatoide/metabolismo , Ácidos Hidroxámicos/farmacología , Metaloendopeptidasas/antagonistas & inhibidores , Inhibidores de Proteasas/farmacología , Receptores del Factor de Necrosis Tumoral/antagonistas & inhibidores , Membrana Sinovial/metabolismo , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Línea Celular , Humanos , Rabdomiosarcoma/patología , Factor de Necrosis Tumoral alfa/farmacologíaRESUMEN
We have studied the cytokine regulation of cell surface and soluble intercellular adhesion molecule 1 (ICAM-1) expression on the human melanoma cell line A375M. Unstimulated cells express ICAM-1 on their cell surface but do not secrete significant levels of soluble ICAM-1. Interleukin 1, interleukin 6, tumor necrosis factor, and gamma-interferon all increased cell surface expression of ICAM-1. Tumor necrosis factor, interleukin 1, and gamma-interferon also caused the release of soluble ICAM-1. The serum of melanoma patients has been reported to contain elevated levels of soluble ICAM-1; however, the source of this ICAM-1 is unclear. The serum from nude mice bearing s.c. human melanoma tumors was found to contain soluble human ICAM-1. ICAM-1 levels showed a positive correlation with tumor weight. The release of ICAM-1 from melanoma tumors, in response to host-derived cytokines, may have relevance to immune recognition of the tumor.
Asunto(s)
Moléculas de Adhesión Celular/metabolismo , Melanoma/metabolismo , Animales , Moléculas de Adhesión Celular/sangre , Humanos , Molécula 1 de Adhesión Intercelular , Interferón gamma/farmacología , Interleucina-1/farmacología , Interleucina-6/farmacología , Melanoma/sangre , Ratones , Ratones Desnudos , Células Tumorales CultivadasRESUMEN
At least 20 different isoforms of the human CD44 lymphocyte-homing receptor/hyaluronan receptor have been described to date that arise from the differential splicing of up to 10 alternative exons (termed v1-v10) encoding the membrane-proximal extracellular domain. Although numerous analyses at the mRNA level have indicated tissue-specific expression of CD44 variants, few analyses have been performed at the protein level because of limited availability of suitable monoclonal antibodies. Recently, however, exon-specific monoclonal antibodies have been generated using bacterial fusion proteins, and these have been reported to detect high levels of vCD44 containing the v6 exon on human tumors. Together with earlier evidence linking this particular exon with tumor metastasis in the rat, these latter experiments have led to the interpretation that v6 splice variants play a causative role in tumor dissemination. In this paper we describe the use of a new and comprehensive panel of CD44 exon-specific monoclonal antibodies generated against a recombinant CD44(v3-10)-immunoglobulin chimera to study vCD44 expression in a large number of normal and neoplastic tissues. We show that the expression of vCD44 varies greatly among different human tumors and that some express either very low levels of vCD44 or no CD44 at all. Furthermore, we demonstrate that expression is not limited to isoforms containing the v6 exon but includes variants carrying v3, v4/5, and v8/9. Additionally, normal epithelial tissues are shown to express considerable levels of these same vCD44 isoforms. Such results argue against a ubiquitous role for vCD44 isoforms in promoting tumor growth and metastasis.
Asunto(s)
Proteínas Portadoras/análisis , Exones/inmunología , Receptores de Superficie Celular/análisis , Receptores Mensajeros de Linfocitos/análisis , Anticuerpos Monoclonales , Especificidad de Anticuerpos , Secuencia de Bases , Proteínas Portadoras/genética , Línea Celular , Epitelio/inmunología , Humanos , Receptores de Hialuranos , Datos de Secuencia Molecular , Neoplasias/inmunología , Receptores de Superficie Celular/genética , Receptores Mensajeros de Linfocitos/genéticaRESUMEN
We have previously reported that treatment with interleukin 1 (IL-1) induced the augmentation of lung tumor colonies by a human melanoma in nude mice. Here we have investigated the involvement of the alpha 4 beta 1 integrin, the very late antigen 4 (VLA-4) in this augmentation. A375M melanoma cells expressed high levels of VLA-4 and preferentially adhered to a surface coated with vascular cell adhesion molecule 1 (VCAM-1), the ligand for VLA-4 on activated endothelial cells. This adhesion was inhibited by treating tumor cells with saturating concentrations of mAb to VLA-4. The production of lung colonies was significantly enhanced in nude mice given an injection of IL-1 before A375M melanoma cells. Immunoperoxidase staining showed that VCAM-1 could be expressed on lung vascular endothelium of mice in response to IL-1. Pretreatment of melanoma cells with a mAb to VLA-4 completely abrogated the IL-1-induced augmentation of lung colonies. Using two metastatic melanoma clones (clones 2/4 and 2/60) that expressed different levels of VLA-4, we found that only VLA-4-bearing cells adhered to a VCAM-1-coated surface and formed enhanced numbers of lung colonies in IL-1-treated nude mice. This augmentation was inhibited by pretreating the tumor cells with anti-VLA-4 mAb. These results demonstrate, in vivo, the functional involvement of VLA-4 on melanoma cells in IL-1-mediated lung colony augmentation, most probably involving the interaction of tumor cells with VCAM-1 on activated endothelial cells.
Asunto(s)
Moléculas de Adhesión Celular/metabolismo , Interleucina-1/farmacología , Neoplasias Pulmonares/secundario , Melanoma/secundario , Receptores de Antígeno muy Tardío/fisiología , Animales , Anticuerpos Monoclonales/farmacología , Adhesión Celular/efectos de los fármacos , Endotelio Vascular/metabolismo , Femenino , Humanos , Neoplasias Pulmonares/irrigación sanguínea , Melanoma/metabolismo , Ratones , Ratones Desnudos , Receptores de Antígeno muy Tardío/antagonistas & inhibidores , Receptores de Antígeno muy Tardío/metabolismo , Células Tumorales Cultivadas , Molécula 1 de Adhesión Celular VascularRESUMEN
Tumor necrosis factor-alpha (TNF-alpha) is released from a cell membrane-anchored precursor by proteolytic cleavage. We have shown that broad spectrum synthetic inhibitors of matrix metalloproteinases (MMPs) prevent the processing of the TNF precursor but do not inhibit the release of other cytokines. Purified MMPs, stromelysin, matrilysin, collagenase, and the gelatinases can all cleave a recombinant pro-TNF substrate to yield mature TNF. MMP inhibitors prevent the rise in blood levels of TNF after endotoxin administration in rats and are effective in animal models of inflammatory disease such as adjuvant arthritis. Drugs that inhibit MMP action and TNF release show great promise for the treatment of autoimmune inflammatory diseases.
Asunto(s)
Metaloendopeptidasas/fisiología , Factor de Necrosis Tumoral alfa/metabolismo , Secuencia de Aminoácidos , Expresión Génica/efectos de los fármacos , Humanos , Datos de Secuencia Molecular , Monocitos/metabolismo , Péptidos/química , Precursores de Proteínas/metabolismo , Procesamiento Proteico-Postraduccional , Proteínas Recombinantes de Fusión/metabolismoRESUMEN
Recombinant human interleukin 1 (IL-1) possesses potent inflammatory properties in both animal and human skin. However, IL-1-like material has been isolated from normal epidermal samples. In view of the uncertainty concerning the structure and biologic properties of human epidermal IL-1, heel stratum corneum, and chamber fluid samples from normal skin have been purified by successive reversed phase and anion exchange high-performance liquid chromatography (HPLC), and aliquots of each HPLC fraction tested for IL-1 activity in an EL-4 NOB-1 assay and for inflammatory activity by intradermal injection of autologous material. The results consistently indicated the presence of inflammatory quantities of IL-1 alpha-like material, which induced persistent erythema lasting at least 24 h, associated in 4-h biopsies with mixed dermal leukocyte infiltrates containing increased numbers of neutrophils, monocytes, and T helper cells. Biologically active quantities of IL-1 beta were not recovered following HPLC purification in most experiments. Analysis of heel stratum corneum extract also showed that the majority of the dilution-related IL-1 activity detected in the EL-4 NOB-1 bioassay was neutralized by IL-1 alpha but not IL-1 beta antiserum. These findings suggest that IL-1 alpha-like material is present in inflammatory amounts in normal human epidermis, and its release may represent a primary inflammatory mechanism in human skin.
Asunto(s)
Dermatitis/fisiopatología , Interleucina-1/fisiología , Fenómenos Fisiológicos de la Piel , Adulto , Cromatografía Líquida de Alta Presión , Femenino , Humanos , Sueros Inmunes/inmunología , Interleucina-1/aislamiento & purificación , Interleucina-1/metabolismo , Leucocitos/patología , Masculino , Persona de Mediana Edad , Valores de Referencia , Piel/metabolismoRESUMEN
The constitutive production of interleukin-1 alpha-like material in normal human epidermis, its inflammatory properties, and the mechanism of its inflammatory action are briefly reviewed. The isolation of interleukin-8 from psoriatic lesions, its in vitro production, and leukocyte chemoattractant properties are also described. Available evidence suggests that interleukins-1 and -8 are inflammatory cytokines of major potential importance in the induction of leukocyte infiltrates in human skin.
Asunto(s)
Factores Quimiotácticos/metabolismo , Quimiotaxis de Leucocito , Epidermis/metabolismo , Humanos , Interleucina-1/metabolismo , Interleucina-8/metabolismo , Psoriasis/metabolismo , Piel/metabolismoRESUMEN
The concentration of porcine interleukin-1 beta (pIL1 beta) required to elicit half-maximal IL2 production from NOB-1, a subline of murine thymoma EL4, was 100-fold greater than for p1L alpha. In contrast, similar doses of each type of IL1 stimulated increased lactate production by Balb/C 3T3 fibroblasts. Receptor-bound 125I-IL 1 alpha was displaced with equal efficiency by both unlabelled forms from 3T3 cells, but a 20-fold lower affinity for p1L1 beta was observed using NOB-1. Crosslinking experiments suggested that the IL1 receptors on each line consisted of two polypeptides of 80 and 100 kDa. The results provide the first evidence for a multiple-component IL1 receptor within which IL1 alpha and IL1 beta may bind at different loci, and suggest the receptors may have evolved differently in the two lines.
Asunto(s)
Fibroblastos/metabolismo , Receptores Inmunológicos/metabolismo , Timoma/metabolismo , Neoplasias del Timo/metabolismo , Animales , Línea Celular , Reactivos de Enlaces Cruzados , Interleucina-1/farmacología , Interleucina-1/fisiología , Interleucina-2/biosíntesis , Lactatos/biosíntesis , Ácido Láctico , Ratones , Ratones Endogámicos BALB C , Receptores de Interleucina-1 , Células Tumorales CultivadasRESUMEN
We have demonstrated that patients with ovarian carcinoma have higher levels of soluble intercellular adhesion molecule-1 (ICAM-1) in their serum and ascitic fluids than serum from normal individuals and non-neoplastic gynaecological disease or ascites from patients with cirrhosis. In order to investigate the source of the ICAM-1, and to study the mechanisms which regulate ICAM-1 release in ovarian carcinoma, we have employed the nude mouse model system. Three different human ovarian carcinoma (HOC) cell lines were grown as ascitic tumours in the peritoneal cavity of nude mice. HOC xenografts harvested from nude mice expressed comparable levels of ICAM-1 on their cell surface. Human ICAM-1 was detected, with a species-specific ELISA, in serum and ascitic fluid of tumour-bearing mice, confirming that the tumours were the source of the ICAM-1. The three HOC xenografts showed different levels of ICAM-1 release, but within each xenograft model the level of ICAM-1 in serum and ascitic fluid correlated with the tumour burden. The level of ICAM-1 released by the HOC xenografts could be increased by in vivo treatment with interferon gamma (IFN-gamma). Interleukin 1 (IL-1), tumour necrosis factor (TNF) and IFN gamma increased the cell surface expression of ICAM-1 and caused the release of soluble ICAM-1 from HOC cells established in vitro. The nude mouse provides a useful system in which to study the effects of modulating ICAM-1 release on the progression of ovarian carcinoma and suggests that measuring ICAM-1 levels in the blood or ascites of patients may provide an indication of tumour burden.
Asunto(s)
Líquido Ascítico/metabolismo , Molécula 1 de Adhesión Intercelular/metabolismo , Neoplasias Ováricas/metabolismo , Animales , Femenino , Humanos , Molécula 1 de Adhesión Intercelular/sangre , Interferón gamma/farmacología , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Neoplasias Ováricas/sangre , Solubilidad , Trasplante Heterólogo , Células Tumorales CultivadasRESUMEN
Three lyophilized preparations of interleukin-2 coded 86/500, 86/564 and 86/504 have been evaluated in an international collaborative study for their suitability as an international standard. All of the preparations performed well in the different bioassay systems included in the study, and showed excellent stability on accelerated temperature degradation. Material similar to that in preparation 86/504 has served well as an interim reference reagent for interleukin-2 for 3 years. Therefore with the agreement of the study participants and the authorization of the Expert Committee on Biological Standardization of the World Health Organization, the preparation coded 86/504 was established in 1987 as the 1st international standard for interleukin-2, with a defined potency of 100 IU/ampoule.
Asunto(s)
Pruebas Inmunológicas de Citotoxicidad/normas , Interleucina-2/normas , Animales , Calibración/normas , Línea Celular , Humanos , Indicadores y Reactivos/normas , Cooperación Internacional , Activación de Linfocitos , Ratones , Proteínas Recombinantes/normas , Linfocitos T/inmunologíaRESUMEN
The use of Tween 20 as a suitable blocking agent in immunoblotting studies was evaluated by screening a panel of monoclonal antibodies (MoAbs) against a selection of blotted proteins which were unrelated to the antigens used to raise the MoAbs. Using Tween 20 alone to block the nitrocellulose membranes clear reactions were observed between the panel of MoAbs and several components of the blotted protein mixture. In contrast, when haemoglobin was used to block the membranes such reactions were not observed. In the absence of added protein the use of Tween 20 alone as a blocking agent for immunoblotting appears to lead to false positive reactions by non-specific antigen-antibody complexes.
Asunto(s)
Complejo Antígeno-Anticuerpo/análisis , Reacciones Antígeno-Anticuerpo , Técnicas de Inmunoadsorción , Polisorbatos , Anticuerpos MonoclonalesRESUMEN
We report here the use of 'single shot' intrasplenic injection of human IgM for immunization of mice to obtain splenocytes for use in the production of hybridomas secreting antibodies against human IgM. Fusion was performed 3 days after intrasplenic injection of 20 micrograms of myeloma IgM. IgM-specific antibodies were found in 12% of the fusion wells; only 1 well contained antibodies which cross-reacted with other immunoglobulin classes. Two monoclonal antibodies (McAbs) have been fully characterized as specific for different epitopes on Fc mu. These antibodies can be used to detect IgM on the surface of human B cells by immunofluorescence and in solution by solid-phase radiobinding assay or single radial immunodiffusion. Both McAbs can also detect IgM fragments by immunoblotting from non-reducing SDS-polyacrylamide gels.
Asunto(s)
Anticuerpos Antiidiotipos/inmunología , Anticuerpos Monoclonales/inmunología , Cadenas Pesadas de Inmunoglobulina/inmunología , Inmunoglobulina M/inmunología , Cadenas mu de Inmunoglobulina/inmunología , Animales , Especificidad de Anticuerpos , Humanos , Hibridomas/inmunología , Esquemas de Inmunización , Fragmentos Fc de Inmunoglobulinas/inmunología , Ratones , Receptores de Antígenos de Linfocitos B/inmunología , Bazo/inmunologíaRESUMEN
Murine monoclonal antibodies and a sheep polyclonal antiserum against recombinant human granulocyte colony-stimulating factor (GCSF) have been produced. These have been used to develop an immunoassay which can detect 250 pg/ml (25 U) of both natural and recombinant human GCSF. The assay involves forming a complex between GCSF and a monoclonal anti-GCSF, binding of the complex to microtitre wells coated with sheep anti-GCSF and detection of the bound complex with 125I-labelled sheep anti-mouse IgG. Unlike the classical bone marrow assay and other cell line based bioassays for GCSF, the immunoassay was specific for the cytokine, showing no cross-reactivity with GM-CSF, IL-6, IL-3 or IL-1 alpha and -beta. The assay does not exhibit interfering matrix effects when used for the estimation of human GCSF in serum.
Asunto(s)
Anticuerpos Monoclonales/aislamiento & purificación , Anticuerpos/aislamiento & purificación , Factores Estimulantes de Colonias/análisis , Radioinmunoensayo/métodos , Animales , Anticuerpos/inmunología , Anticuerpos Monoclonales/inmunología , Línea Celular , Factores Estimulantes de Colonias/inmunología , Factor Estimulante de Colonias de Granulocitos , Humanos , Immunoblotting , Ratones , Ratones Endogámicos BALB C , OvinosRESUMEN
A subclone, NOB-1, of the mouse EL-4 line constitutively produces very little interleukin-2 but in response to interleukin-1 produces high concentrations of interleukin-2. Co-stimulation with mitogen, phorbol esters or calcium ionophores was not required. NOB-1 is not responsive to tumour necrosis factor alpha, tumour necrosis factor beta, interferon gamma and lipopolysaccharide. The NOB-1 line was used in conjunction with a CTLL line to detect less than 1 pg/ml interleukin-1. Rapid assay was performed by co-culturing the EL-4 cells with CTLL cells. By incorporating a pre-incubation step, followed by thorough washing of the EL-4 cells, responses to interleukin-1 were maintained, but interleukin-2 had no effect. The assay was used to detect interleukin-1 in serum samples and to evaluate neutralizing antisera to interleukin-1.
Asunto(s)
Bioensayo , Interleucina-1/análisis , Interleucina-2/análisis , Proteínas Recombinantes/análisis , Animales , Línea Celular , Relación Dosis-Respuesta a Droga , Humanos , Interleucina-1/inmunología , Interleucina-2/inmunología , Activación de Linfocitos/efectos de los fármacos , Ratones , Pruebas de Neutralización , Conejos , Especificidad por SustratoRESUMEN
Alzheimer's disease (AD) is the commonest form of adult onset dementia and is characterised neuropathologically by the accumulation of plaques containing beta-amyloid (A beta) fibrils, reactive astrocytes, activated microglia, and leukocytes. A beta plays a role in the pathology of AD by directly causing neuronal cytotoxicity and stimulating microglia to secrete cytokines and reactive oxygen species (ROS) which also damage neurons. Here, we demonstrate that A beta activates astrocytes and oligodendrocytes (the most common cell types in the brain) to produce chemokines, in particular MCP-1 and RANTES, which serve as potent in vitro microglial and macrophage chemoattractants. Furthermore, we have shown that A beta activates astrocytes to upregulate pro-inflammatory cytokine expression and enhances the production of ROS. We propose therefore that A beta-mediated astrocyte activation initiates an inflammatory cascade which could be targeted for therapeutic intervention in AD.
Asunto(s)
Péptidos beta-Amiloides/inmunología , Astrocitos/inmunología , Quimiocina CCL2/inmunología , Quimiocina CCL5/inmunología , Quimiocinas CXC , Péptidos y Proteínas de Señalización Intercelular , Fragmentos de Péptidos/inmunología , Especies Reactivas de Oxígeno/inmunología , Enfermedad de Alzheimer/inmunología , Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/farmacología , Animales , Astrocitos/citología , Astrocitos/efectos de los fármacos , Encéfalo/citología , Encéfalo/inmunología , Quimiocina CCL2/genética , Quimiocina CCL5/genética , Quimiocina CXCL2 , Factores Quimiotácticos/genética , Factores Quimiotácticos/inmunología , Quimiotaxis/efectos de los fármacos , Quimiotaxis/inmunología , Expresión Génica/inmunología , Inhibidores de Crecimiento/genética , Inhibidores de Crecimiento/inmunología , Sustancias de Crecimiento/genética , Sustancias de Crecimiento/inmunología , Macrófagos/citología , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Microglía/citología , Microglía/efectos de los fármacos , Microglía/inmunología , Monocinas/genética , Monocinas/inmunología , Neuritis/inmunología , Oligodendroglía/citología , Oligodendroglía/efectos de los fármacos , Oligodendroglía/inmunología , Sondas de Oligonucleótidos , Fragmentos de Péptidos/farmacología , Ratas , Ratas WistarRESUMEN
The effects of anti-inflammatory drugs on glial immunity and neuropathology were determined in a severe combined immune deficiency (SCID) mouse model of HIV-1 encephalitis. HIV-1-infected human monocyte-derived macrophages (MDM) are stereotactically inoculated into basal ganglia resulting in a multinucleated giant cell encephalitis. A platelet activating factor antagonist and a matrix metalloproteinase inhibitor, which also inhibits tumor necrosis factor alpha release, were administered to animals at the time of the MDM inoculation. The drugs administered in combination markedly reduced brain inflammation, astrogliosis and microglia activation. These findings demonstrate that reduction of brain inflammatory responses, independent of viral replication, can affect HIVE pathology in an animal model system of disease.
Asunto(s)
Complejo SIDA Demencia/inmunología , Inhibidores de la Metaloproteinasa de la Matriz , Microglía/inmunología , Factor de Activación Plaquetaria/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Complejo SIDA Demencia/tratamiento farmacológico , Animales , Compuestos de Bencilo , Supervivencia Celular/inmunología , Dexametasona/farmacología , Modelos Animales de Enfermedad , Combinación de Medicamentos , Gliosis/inmunología , VIH-1 , Humanos , Técnicas In Vitro , Interleucina-1/metabolismo , Interleucina-8/metabolismo , Leucina/análogos & derivados , Leucina/farmacología , Macrófagos/inmunología , Macrófagos/metabolismo , Masculino , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Ratones , Ratones SCID , Microglía/patología , Microglía/virología , Neuronas/inmunología , Neuronas/patología , Pentoxifilina/farmacología , Factor de Activación Plaquetaria/biosíntesis , Inhibidores de Proteasas/farmacología , Succinatos , Factor de Crecimiento Transformador beta/metabolismo , Factor de Necrosis Tumoral alfa/biosíntesisRESUMEN
The matrix metalloproteinases (MMPs) are a family of at least 14 zinc-dependent enzymes which are known to degrade the protein components of extracellular matrix. In addition, MMPs and related enzymes can also process a number of cell surface cytokines, receptors, and other soluble proteins. In particular we have shown that the release of the pro-inflammatory cytokine, tumor necrosis factor-alpha, from its membrane-bound precursor is an MMP-dependent process. MMPs are expressed by the inflammatory cells which are associated with CNS lesions in animal models of multiple sclerosis (MS) and in tissue from patients with the disease. MMP expression will contribute to the tissue destruction and inflammation in MS. Drugs which inhibit MMP activity are effective in animal models of MS and may prove to be useful therapies in the clinic.
Asunto(s)
Metaloendopeptidasas , Esclerosis Múltiple/enzimología , Esclerosis Múltiple/inmunología , Factor de Necrosis Tumoral alfa , Animales , Humanos , Metaloendopeptidasas/antagonistas & inhibidores , Metaloendopeptidasas/fisiología , Esclerosis Múltiple/patología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/fisiologíaRESUMEN
Matrix metalloproteinases (MMPs) are a large family of Zn2+ endopeptidases that are expressed in inflammatory conditions and are capable of degrading connective tissue macromolecules. MMP-like enzymes are also involved in the processing of a variety of cell surface molecules including the pro-inflammatory cytokine TNF-alpha. MMPs and TNF-alpha have both been implicated in the pathology associated with neuro-inflammatory diseases (NIDs), particularly multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). We have shown that BB-1101, a broad spectrum hydroxamic acid-based combined inhibitor of MMP activity and TNF processing, reduces the clinical signs and weight loss in an acute EAE model in Lewis rats. However, little is known about which MMPs are involved in the neuroinflammatory process. In order to determine the optimum inhibitory profile for an MMP inhibitor in the treatment of NID, we investigated the profile of MMP expression and activity during EAE. The development of disease symptoms was associated with a 3-fold increase in MMP activity in the cerebrospinal fluid (CSF), which could be inhibited by treatment with BB-1101, and an increase in 92 kDa gelatinase activity detected by gelatin substrate zymography. Quantitative PCR analysis of normal and EAE spinal cord revealed the expression of at least seven MMPs. Of these, matrilysin showed the most significant change, being elevated over 500 fold with onset of clinical symptoms and peaking at maximum disease severity. Of the other six MMPs detected, 92 kDa gelatinase showed a modest 5 fold increase which peaked at the onset of clinical signs and then declined during the most severe phase of the disease. Matrilysin was localised by immunohistochemistry to the invading macrophages within the inflammatory lesions of the spinal cord. Matrilysin's potent broad spectrum proteolytic activity and its localisation to inflammatory lesions in the CNS suggest this enzyme could be particularly involved in the pathological processes associated with neuro-inflammatory disease.
Asunto(s)
Encefalomielitis Autoinmune Experimental/metabolismo , Matriz Extracelular/enzimología , Metaloendopeptidasas/metabolismo , Inhibidores de Proteasas/farmacología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Animales , Compuestos de Bencilo , Dexametasona/farmacología , Combinación de Medicamentos , Encefalomielitis Autoinmune Experimental/líquido cefalorraquídeo , Inmunohistoquímica , Masculino , Metaloproteinasa 7 de la Matriz , Metaloendopeptidasas/antagonistas & inhibidores , Metaloendopeptidasas/líquido cefalorraquídeo , Pentoxifilina/farmacología , Reacción en Cadena de la Polimerasa , Ratas , Ratas Endogámicas Lew , Médula Espinal/metabolismo , SuccinatosRESUMEN
In an experimentally-induced DTH model of MS, we examined mRNA and protein expression of a range of MMPs and of TNFalpha to establish the contribution that individual MMPs might make to the pathogenesis. In control rat brain, mRNA for all of the MMPs examined was detectable. However, by immunohistochemistry, only MMP-2 could be detected. In the DTH lesions, significant increases in the level of mRNA expression were observed for MMP-7, MMP-8, MMP-12, and TNFalpha. Where expression of MMP mRNA was increased, there was a corresponding increase in protein expression detected by immunohistochemistry. To determine whether the upregulated MMPs could invoke destructive events in the CNS, highly purified activated MMP-7, MMP-8, and MMP-9 were stereotaxically injected into the brain parenchyma. All provoked recruitment of leukocytes and BBB breakdown. In addition, MMPs 7 and 9 induced loss of myelin staining. In conclusion, specific MMPs are upregulated in DTH lesions; for the most part, measurement of mRNA was a predictor of increased protein expression. From our injections of MMPs, it is clear that the upregulated MMPs in the DTH lesions could participate in the disruption of the BBB, leukocyte recruitment, and tissue damage.
Asunto(s)
Matriz Extracelular/metabolismo , Hipersensibilidad Tardía/metabolismo , Metaloendopeptidasas/metabolismo , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/patología , Movimiento Celular/fisiología , Modelos Animales de Enfermedad , Hipersensibilidad Tardía/patología , Inmunohistoquímica , Inyecciones , Leucocitos/fisiología , Masculino , Metaloendopeptidasas/genética , Metaloendopeptidasas/farmacología , Esclerosis Múltiple/metabolismo , Esclerosis Múltiple/patología , Reacción en Cadena de la Polimerasa , ARN Mensajero/metabolismo , Ratas , Ratas Endogámicas LewRESUMEN
The effect of treatment with a broad-spectrum inhibitor (BB1101) of the matrix metalloproteinases (MMPs) on nerve regeneration and functional recovery after nerve crush was examined. Drug treatment had no effect on latency but from 63 days the compound muscle action potential was significantly increased and was no different to that in the sham-operated controls at 72 days. Levels of MMP mRNA expression, and the localisation and activity of MMP proteins, were examined in rats for a 2 month period following a nerve crush injury, and compared with sham-operated controls. The mRNA of all the MMPs studied was up-regulated by 5-10 days after nerve crush, and they remained up-regulated for 40-63 days, except for MMP-9 which was down-regulated by 10 days. MMP immunoreactivity was localised to Schwann cells, macrophages and endothelial cells, and with the exception of membrane type 1-MMP (MT1-MMP), it was more intense after nerve crush compared with sham-operated controls. Regenerating axons showed immunoreactivity for MMP-2 and MMP-3. In situ zymography confirmed that the activity of MMPs in the nerve was increased following crush but that the activity was greatly reduced in rats treated with BB-1101. Thus despite the inhibition of MMPs by BB-1101, the drug did not appear to essentially affect nerve degeneration or regeneration following nerve crush but that it could be beneficial in promoting the more effective reinnervation of muscles possibly by actions at the level of the muscles.